Breaking News

AbbVie Acquires Syndesi for $130M Upfront

Expands neuroscience portfolio with novel modulators of the synaptic vesicle protein 2A, including Syndesi's lead molecule SDI-118.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie has acquired Syndesi Therapeutics SA, expanding AbbVie’s neuroscience portfolio. Syndesi’s portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), include its lead molecule SDI-118. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer’s disease and major depressive disorder.     AbbVie will pa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters